Skip to main content

Zavicefta and the Fight Against Antimicrobial Resistance: Why It Matters Now More Than Ever

Introduction 

Antimicrobial resistance (AMR) occurs when germs no longer respond to treatment, making infections harder to cure and increasing the risk of severe illness. This growing resistance also threatens routine medical procedures that depend on effective antibiotics. AMR adds major costs to healthcare and society, often leading to the need for more specialised and expensive treatment. To protect future treatment options, health authorities are exploring new approaches to support the development of effective antimicrobials.1 

Understanding the Global Threat of AMR 

AMR is increasing at an alarming rate around the world. It is estimated that drug-resistant infections already cause hundreds of thousands of deaths each year and could rise dramatically if unchecked.1 

AMR affects not only patients but entire healthcare systems and economies. Hospitals face longer patient stays, more complicated treatments, and higher costs when infections are drug-resistant. On a societal level, productivity suffers, and agriculture can also be affected, as resistant infections impact livestock and food safety. Tackling this challenge requires coordinated action, including infection-control programs, careful antibiotic use and investment in new medicines.1 

One such option is Zavicefta, a newer antibiotic combination designed specifically for serious, hard-to-treat infections.2 

Zavicefta: How This Antibiotic Fights Hard-to-Treat Infections 

Zavicefta is an intravenous antibiotic that combines ceftazidime, a traditional antibiotic, with avibactam, a helper medicine that protects it. This combination is used to treat serious infections caused by bacteria that are resistant to many other antibiotics.2 

Ceftazidime works by attacking the bacterial cell wall to kill the bacteria. Some bacteria, however, produce enzymes that can destroy ceftazidime before it works. Avibactam blocks these enzymes, allowing the antibiotic to remain effective. This makes Zavicefta especially useful for infections that are difficult to treat because the bacteria have developed resistance.2 

Clinical Indications: Where Zavicefta Makes the Difference 

The dual action of Zavicefta can help doctors manage serious infections.2 

Zavicefta is used for infections of the stomach and gut (abdomen), those of the bladder or kidneys called urinary tract infections, an infection of the lungs called pneumonia, infections caused by bacteria that other antibiotics may not be able to kill – these conditions often require hospital‑based care under specialist supervision.2 

How Doctors Decide When to Use Zavicefta (Approvals, Guidelines & Hospital Use) 

Zavicefta is approved in many parts of the world, including the European Union and the United States, for treating serious infections caused by bacteria that are resistant to many commonly used antibiotics.3,4 These infections often occur in very sick patients, so treatment decisions must be made with great care.5 

Because Zavicefta is designed for difficult-to-treat infections, doctors follow strict clinical guidelines when considering it. According to expert recommendations, the medicine should be used only when tests show that the bacteria are not likely to respond to safer or more common antibiotics. Disease specialists are usually involved in reviewing lab results, checking resistance patterns and confirming whether this drug is the most effective and safest choice.5 

In urgent cases – especially when a patient is severely unwell – doctors may begin Zavicefta before full test results return, but only if the infection is expected to respond to it and delay could be harmful.5 This careful approach helps patients receive the best possible treatment while also protecting the antibiotic from overuse, ensuring it remains effective for future patients who may need it.5 

Safety and Side-Effects Profile 

Zavicefta is generally well-tolerated in clinical studies, but like all antibiotics it can cause side effects.6 Because it is used for serious infections and given as a drip into the vein, doctors monitor patients closely while they receive it.2 

Many patients experience mild side effects such as headache or dizziness, nausea or stomach discomfort, or temporary changes in digestion such as diarrhoea. Some may develop fungal infections, experience itchy skin rashes or hives or notice redness or discomfort at the site where the medicine is given. Fever is another common reaction reported with treatment.2 

Less frequently, some patients may feel tingling or numbness or notice a temporary bad taste in the mouth. Medical teams may monitor kidney function during treatment as a precaution, though serious kidney problems are rare.2 

What patients can do: 

  • Tell your doctor about any drug allergies and all medicines you're taking2 

  • Inform the care team if you develop rash, worsening diarrhoea, unusual tiredness or yellowing of the skin/eyes2 

Antimicrobial Stewardship: How Patients Can Help 

Antimicrobial stewardship means using antibiotics carefully to keep them effective for everyone.7 Patients play an important role too. You can help by following your healthcare professional’s instructions carefully and reporting any side effects that you notice.7 

Other ways to support safe use include not taking leftover medicines from a previous illness and safely disposing of any unused medications. Taking precautions – like handwashing, staying home when sick and keeping up with recommended vaccines – also helps prevent infections.7 

By following these steps, patients help make sure antibiotics like Zavicefta remain effective for those who truly need them, now and in the future. 

Barriers to Access and Affordability 

Even though Zavicefta is approved for serious, hard-to-treat infections, not all patients can access it easily. In some hospitals, the medicine may be limited or costly, making timely treatment more challenging.8  

Doctors also rely on laboratory tests to determine which infections are most likely to respond. Without this testing, it can be difficult to decide when Zavicefta is the safest and most effective option.8 

Accessing Zavicefta in India Through the Named Patient Program 

Zavicefta is approved for use in many countries, but it is not yet widely available in India. Patients can still access it through the Named Patient Program (NPP), a special pathway that allows doctors to request medicines that are not commercially available locally when treatment options are limited.9 

Your infectious disease specialist or treating doctor can apply for Zavicefta under the NPP by submitting your medical details and justification for use. The process involves regulatory approvals and import arrangements, after which the medicine is supplied directly to your hospital. 

To simplify this process, Rx4U supports patients and caregivers by managing the paperwork, coordinating with healthcare providers, and ensuring timely import and delivery of Zavicefta, so treatment can begin without unnecessary delays. 

Final Takeaway 

  • Zavicefta is an antibiotic used to treat serious, hard-to-treat infections caused by certain bacteria. 

 

  • It works by combining two components that help kill bacteria, including some that are resistant to other antibiotics. 

  • In India, Zavicefta can be accessed via the NPP with support from Rx4U. 

Frequently Asked Questions 

1. Can Zavicefta be used in children? 

Zavicefta is approved for use in children aged 3 months and older, depending on the type of infection. Your doctor will decide the right dose based on age, weight, and the infection being treated.² 

2. What about use during pregnancy or breastfeeding? 

Zavicefta should only be used during pregnancy or breastfeeding if clearly needed. Your doctor will weigh the benefits and risks before prescribing.² 

3. How is Zavicefta given? 

Zavicefta is given through an intravenous (IV) infusion, usually in a hospital setting, under the supervision of healthcare professionals.² 

 

Medical Disclaimer 

This information is provided for educational purposes only and is not a substitute for professional medical advice. Zavicefta should only be taken under the guidance of a qualified healthcare provider. Patients should always consult their doctor or pharmacist for advice on diagnosis, treatment, and medication use, and should not make changes to their prescribed therapy without medical supervision. 

 

References: 

  1. Antimicrobial resistance. World Health Organization. November 21, 2023. Accessed December 5, 2025. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance 

  1. Zavicefta. Summary of product characteristics. Pfizer Ireland Pharmaceuticals Unlimited Company. Updated May 20, 2025. Accessed December 5, 2025. https://www.ema.europa.eu/en/documents/product-information/zavicefta-epar-product-information_en.pdf 

  1. New medicine to help in the fight against antimicrobial resistance. News release. European Medicines Agency. April 29, 2016. Accessed December 5, 2025. https://www.ema.europa.eu/en/news/new-medicine-help-fight-against-antimicrobial-resistance 

  1. Avycaz. Prescribing information. GlaxoSmithKline Manufacturing. March 2019. Accessed December 5, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206494s005,s006lbl.pdf 

  1. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections. NICE Guidance. August 17, 2022. Accessed December 5, 2025. https://www.nice.org.uk/guidance/hte1/resources/ceftazidime-with-avibactam-for-treating-severe-drugresistant-gramnegative-bacterial-infections-pdf-1396165638085 

  1. Shirley M. Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections. Drugs. 2018;78(6):675-692. doi:10.1007/s40265-018-0902-x 

  1. Antimicrobial stewardship. Mayo Clinic. June 19, 2024. Accessed December 5, 2025. https://www.mayoclinic.org/departments-centers/antimicrobial-stewardship/overview/ovc-20564612  

  1. Raveendran S, Deepashree R, Shimoga Ravi Kumar S, Karthik K. Addressing the global threat of multidrug-resistant infections: the role of ceftazidime-avibactam revisited. Cureus. 2024;16(5):e60235. doi:10.7759/cureus.60235 

  1. Patil S. Early access programs: benefits, challenges, and key considerations for successful implementation. Perspect Clin Res. 2016;7(1):4-8. doi:10.4103/2229-3485.173779 

 

Labels:

Comments

Post a Comment

Popular posts from this blog

How Can Leqvio Help Manage Cholesterol Effectively?

  Effects of Cholesterol on a Patient’s Life Cholesterol is a waxy, fat-like substance essential for the body’s normal function. However, excessive levels of low-density lipoprotein (LDL), commonly known as 'bad cholesterol,' can lead to severe health issues. High cholesterol significantly increases the risk of cardiovascular diseases (CVDs), including heart attacks and strokes. 1 Individuals with high cholesterol often experience complications such as atherosclerosis, where plaque builds up in the arteries, restricting blood flow. 2 This condition can lead to chest pain (angina), peripheral artery disease, and even chronic kidney disease due to reduced blood supply. 3 Cardiovascular diseases account for nearly one-third of all deaths worldwide, making cholesterol management crucial. 4 Elevated LDL cholesterol contributes to the formation of plaques that can rupture, causing life-threatening complications. Managing cholesterol effectively through lifestyle modifications, diet...
Post a Comment
Read more

How Zolgensma, a Gene Therapy, is Rewriting The Fate of SMA (Spinal Muscular Atrophy) Patients

What is Spinal Muscular Atrophy (SMA) ?  1   SMA is a rare inherited disease that weakens muscles over time, making movement difficult. It happens because motor neurons, the nerve cells that control muscles , break down and die .     How does it happen? 1   SMA is caused by a fault in a gene called SMN1. This gene normally produces a protein (SMN protein) that keeps motor neurons healthy .     When the SMN1 gene is broken, the body doesn’t make enough SMN protein, leading to muscle weakness and wasting. The effect? Without enough SMN protein, muscles get weaker, affecting activities like crawling, walking, swallowing, and in some severe cases - even breathing!   Types of SMA: 1   1. Type 1 (Severe) – Symptoms at birth or before 6 months . Weak muscles, breathing/eating difficulties .     2. Type 2 (Intermediate) – Appears at 6– 18 months of age. Babies c an sit but not walk. There is p rogressive deterioration in ...
Post a Comment
Read more

How Can Leqvio Help Manage Cholesterol Effectively?

  Cholesterol: Cholesterol is a waxy, fat-like substance essential for the body’s normal function. However, excessive levels of low-density lipoprotein (LDL), commonly known as 'bad cholesterol,' can lead to severe health issues. High cholesterol significantly increases the risk of cardiovascular diseases (CVDs), including heart attacks and strokes. 1 Impact of cholesterol: Individuals with high cholesterol often experience complications such as atherosclerosis, where plaque builds up in the arteries, restricting blood flow. 2 This condition can lead to chest pain (angina), peripheral artery disease, and even chronic kidney disease due to reduced blood supply. 3 Cardiovascular diseases account for nearly one-third of all deaths worldwide, making cholesterol management crucial. 5 Elevated LDL cholesterol contributes to the formation of plaques that can rupture, causing life-threatening complications. Managing cholesterol effectively through lifestyle modifications, die...
Post a Comment
Read more